Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00112034 · ClinicalTrials.gov registry record · Phase 4

AVONEX® Combination Trial - "ACT"

A Phase 4 study, sponsored by Biogen.

Completed
Registry status
Phase 4
Development phase
350
Enrollment target

NCT00112034: Completed Phase 4 study, sponsored by Biogen.

NCT00112034 is a Phase 4 study that has completed, run by Biogen. The registered enrollment target is 350 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00112034, a Phase 4 study, has completed, sponsored by Biogen.

COMPLETED
Registry status
Phase 4
Development phase
350 participants
Enrollment target

Study Summary

The purpose of this study is to determine the efficacy and safety of combination therapy with AVONEX plus low dose oral methotrexate (MTX), every other month courses of intravenous methylprednisolone (IVMP), or both in patients with continued disease activity on AVONEX monotherapy.

Interventions

  • DRUG Methotrexate
  • DRUG IV methylprednisolone

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2003-06
Est. Completion 2007-05
Phase Phase 4
Biogen

334 total trials

What the finished NCT00112034 record still lists

NCT00112034 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (32% lower).

The record links to 0 conditions, and to 2 interventions - of which Methotrexate is the first listed.

NCT00112034 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00112034 about?

NCT00112034 is a clinical study titled "AVONEX® Combination Trial - "ACT"". The purpose of this study is to determine the efficacy and safety of combination therapy with AVONEX plus low dose oral methotrexate (MTX), every other month courses of intravenous methylprednisolone (IVMP), or both in patients with continued disease activity on AVONEX monotherapy.

What is the current status of trial NCT00112034?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 350 participants. The study started on 2003-06. Estimated completion is 2007-05.

What interventions are being tested in trial NCT00112034?

The interventions under investigation include: Methotrexate (DRUG), IV methylprednisolone (DRUG).

Who is sponsoring clinical trial NCT00112034?

This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00112034's enrollment target sits among peer trials

350 231st of 2000 higher than 1,761 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00900575 · 350 participants · NA

    Cervical Cancer Detection Using Optical Spectroscopy

  • NCT01627821 · 350 participants · NA

    Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study

  • NCT02357654 · 350 participants · Phase 4

    GnRH for Luteal Support in IVF/ICSI/FET Cycles

  • NCT03997370 · 350 participants · Phase 1

    Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00112034, the US trial registry maintained by the National Library of Medicine. NCT00112034 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.